Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2947-2952

  Gaspar, M J ^a   De Miguel, J ^b   Garcia Diaz J D ^b   Diez M ^b  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

CA 125; CA 15.3; CA 19.9; CEA; Pleural effusions; TAG 72; Tumour markers

Indexed keywords

CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN TAG 72; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THORACOSCOPY; THORACOTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PARANEOPLASTIC SYNDROMES; PLEURAL EFFUSION, MALIGNANT; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 55749093995     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Marel M, Stastny B, Melinova L, Svandova E and Light RW: Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 107: 1598-1603, 1995.
2. Menzies R and Charbonneau M: Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 114: 271-276, 1991.
3. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B and Estenoz-Alfaro J: Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer 78: 736-740, 1996.
4. Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, Reyre J, Carles P and Serre G: Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 81: 1059-1065, 1999.
5. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S and Orriols R: Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 86: 1488-1495, 1999.
6. Hernandez L, Espasa A, Fernandez C, Candela A, Martin C and Romero S: CEA and CA 549 in serum and pleural fluid of patients with pleural effusion. Lung Cancer 36: 83-89, 2002.
7. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuño-de-Solo B and Estenoz-Alfaro J: Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 40: 289-294, 2003.
8. Porcel JM, Vives M, Esquerda A, Salud A, Perez B and Rodriguez-Panadero F: Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 126: 1757-1763, 2004.
9. Trapé J, Molina R and Sant F: Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 25: 276-281, 2004.
10. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E and Demir S: Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 31: 9-16, 2001.
11. Lee JH and Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 128: 2298-2303, 2005.
12. Light RW, Macgregor MI, Luchsinger PC and Ball WC Jr: Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77: 507-513, 1972.
13. Porcel JM and Light RW: Diagnostic approach to pleural effusion in adults. Am Fam Physician 73: 1211-1220, 2006.
14. Hanley JA and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843, 1983.
15. Garcia-Pachon E, Padilla-Navas I, Dosda MD and Miralles-Llopis A: Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 111: 643-647, 1997.
16. Lee YC and Light RW: Management of malignant pleural effusions. Respirology 9: 148-156, 2004.
17. Light RW: The undiagnosed pleural effusion. Clin Chest Med 27: 309-319, 2006.
18. Ferrer J, Roldan J, Teixidor J, Pallisa E, Gich I and Morell F: Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy. Chest 127: 1017-1022, 2005.
19. Li CS, Cheng BC, Ge W and Gao JF: Clinical value of CYFRA 21-1, NSE, CA 15-3, CA 19-9 and CA 125 assay in the elderly patients with pleural effusions. Int J Clin Pract 61: 444-448, 2007.
20. Shitrit D, Zingerman B, Shitrit AB, Shlomi D and Kramer MR: Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 10: 501-507, 2005.
21. Wagner IC, Guimaraes MJ, da Silva LK, de Melo FM and Muniz MT: Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA 21-1 and CA 15-3 in patients with pleural effusion. J Bras Pneumol 33: 185-191, 2007.
22. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S and Felletti R: Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 119: 1138-1142, 2001.
23. Garcia-Pachon E: Tumor markers for diagnosing malignant pleural effusion? Chest 121: 302-303, 2002.
24. Light RW: Tumor markers in undiagnosed pleural effusions. Chest 126: 1721-1722, 2004.